Lewis H.,Blizzard Institute of Cell and Molecular Science |
Foster G.,Blizzard Institute of Cell and Molecular Science
Clinical Practice | Year: 2013
Hepatitis C virus (HCV) is the leading cause of chronic liver disease and liver transplantation worldwide, with an estimated 170 million people chronically infected. Pegylated interferon and ribavirin (PR) have been the mainstay of treatment for the past 10 years with sustained viral response rates of 41-82%. The use of PR is limited by its side-effect profile, the prolonged treatment course required and its relatively low efficacy. Recently, two new therapies have been approved for the treatment of chronic genotype 1 HCV in combination with PR, the first-generation protease inhibitors telaprevir (TVR) and boceprevir. Phase III clinical trials show that triple therapy with these agents significantly improves sustained viral response rates over PR, but with an increase in adverse events. In this article, we discuss the development of TVR, the current evidence supporting its use in genotype 1 HCV and give practical guidance on the use of TVR in clinical practice. © 2013 Future Medicine Ltd.